Suzhou Basecare Medical (HKG:2170) saw its shares surge by nearly 10% on Wednesday after the company announced that it has obtained approval for the renewal of the registration certificate for its PGT-A kit from China's National Medical Products Administration.
The PGT-A kit is used for accurately detecting DNA abnormalities in embryos, and the renewed registration certificate is valid until February 20, 2030.
The positive regulatory development for one of the company's key products was welcomed by investors, driving the stock price higher on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。